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Doxorubicin (Adriamycin) and daunorubicin are
two clinically important anthracycline antitumour
drugs (Muggia & Rosencweig, 1983). The
development of acquired resistance to doxorubicin
(DOX) and daunorubicin (DAU) is a serious
problem associated with repeated courses of
chemotherapy, and numerous studies have focussed
on determining the characteristics of DOX-resistant
and DAU-resistant cells and evaluating approaches
to circumvent resistance (Dano, 1976; Ganapathi &
Grabowski, 1983; Inaba & Johnson, 1978; Riehm &
Biedler, 1972; Skovsgaard, 1980; Tsuruo et al.,
1982). In DOX-resistant and DAU-resistant tumour
models, resistance to the cytotoxic effects of DAU
and DOX has been suggested to be due to reduced
cellular accumulation and/or retention of drug
(Inaba et al., 1979; Skovsgaard, 1978). The
phenomenon of reduced cellular drug levels as a
mechanism of resistance is substantiated by studies
which have demonstrated that augmentation of
cellular accumulation of DAU and DOX with
Tween 80, calmodulin inhibitors and calcium
antagonists can significantly enhance the cytotoxic
response (Ganapathi & Grabowski, 1983; Inaba &
Johnson, 198; Riehm & Biedler, 1972; Tsuruo et al.,
1982). The relationship, however, between cellular
anthracycline levels and resistance is not true for
the potent lipophilic anthracyclines, which are
accumulated to a similar extent by DOX-sensitive
and DOX-resistant cells (Ganapathi et al., 1984a).
Furthermore, since enhanced cytotoxicity in the
presence of the calmodulin inhibitor trifluoperazine
(TFP) is observed only with strong and not weak
DNA binding antitumor agents (Ganapathi et al.,
1984a; 1985a), the mechanism(s) of resistance to
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strong and weak DNA-binding anthracyclines in
DOX-resistant cells is possibly different. Thus
calmodulin inhibitors may play an important role
in mediating cytotoxicity of strong DNA binding
antitumor agents by mechanism(s) not fully
understood.
Anti-tumour drug resistance when produced
experimentally is usually carried to a high level, so
that differences between the parental-sensitive and
the resistant subline are maximized to enable
identification of the mechanisms of resistance under
optimal conditions (Frei, 1982; Wheeler et al.,
1982). The DOX-resistant (P388/DOX) P388 mouse
leukaemia model system is >100-fold resistant to
DOX, and mechanism(s) of resistance in this model
may be different from those observed clinically.
However, since the cellular pharmacokinetics of
anthracyclines and the effect of TFP on the
cytotoxicity of anthracylines have been extensively
studied in P388/DOX cells, it represents a model
system wherein a clearer understanding of the
mechanism(s) of anthracycline resistance and scope
for modulation, may be possible. Furthermore, the
characteristics of DOX-resistance in P388/DOX
cells, and the effects of TFP on cytotoxicity of
DOX, have been observed in other progressively
DOX-resistant tumour model systems in vitro and
in vivo (unpublished observations). In the present
study, using the P388/DOX cells, we demonstrate
that although similar cellular DOX and DAU levels
in the absence and presence of TFP can be
achieved, perturbations in cell cycle traverse and
cytotoxicity occur only with TFP treatment.
The source of P388/DOX cells and conditions for
their maintenance in vitro are similar to those
described earlier in detail (Ganapathi & Grabowski,
1983; Ganapathi et al., 1984a). The P388/DOX cells
in RPMI 1640 supplemented with 25mM N-2-
hydroxy-ethylpiperazine-N-ethanesulfonic acid and
© The Macmillan Press Ltd., 1986562 R. GANAPATHI et al.
10% foetal bovine serum (FBS) were subcultured at
a density of _0.1 x 106cellsml-1, incubated at
37°C for 24h, and subsequently used for the in
vitro cytotoxicity studies. At initiation of drug
treatment, cells were in log-phase at a density of
-0.4 x 106cellsml-1, and prior to plating in soft-
agar, cell counts in control and treated cultures
were not greater than 1.5 x 106cellsml- . In short-
term drug exposure studies, P388/DOX cells were
treated for 3h and 6h with 0.5pgml-1 and
2.0,igml-1 of DOX in the absence and presence of
5/pM TFP, washed, resuspended in drug-free
medium, and incubated at 37°C in a humidified
atmosphere of 5% CO2 plus 95% air for an
additional 24h. Long term drug exposure studies
involved continuous treatment of P388/DOX cells
for 24h at 37°C in a humidified 5% CO2 plus 95%
air atmosphere with O.l,ugml-P, 0.25ygml-' and
0.5jgml-1 of DAU and 0.25ugml-', 0.5pgml-'
and 1.0ygml- 1 of DOX in the absence and
presence of 5uM TFP. Specific studies carried out
on control and treated P388/DOX cells were: (a)
colony formation in soft-agar; (b) laser flow
cytometry (FCM) for analysis of cellular DAU and
DOX levels (only with cells treated for 24h); and
(c) flow cytometric analysis of cellular DNA
content for cell cycle phase distribution analysis.
Aliquots of control and treated (3 h, 6h and 24h)
P388/DOX cells were washed twice with drug free
RPMI 1640 supplemented with 10% FBS, and
plated (1.5 x 104 trypan blue dye-excluding
cells/Petri-dish) in triplicate in 35 x 10mm Petri-
dishes. Methodological details of the plating
medium, incubation conditions and analysis of
colony growth in the soft agar assay of P388/DOX
cells are similar to those described earlier in detail
(Ganapathi et al., 1984a).
A Becton-Dickinson FACS-II cell sorter was
used for FCM analysis of cellular DAU and DOX
fluorescence (Ganapathi et al., 1984b; 1985b). Cells
following treatment were centrifuged at 4°C,
resuspended in ice-cold drug free RPMI 1640
supplemented with 10% FBS and analyzed at a
flow rate of - 300cellssec-1 at an excitation
wavelength of 488nM, laser power of 0.3W, and
photomultiplier voltage of 650 volts. The pho-
tomultiplier was preceded by two 520 LP filters and
one 530 LP filter. The percentage of cells with
detectable DAU or DOX fluorescence was
quantified by calculating the number of cells
detected by light scatter (LS) versus the number
detected based on cellular fluorescence (FL). The
intensity of cellular DAU or DOX fluorescence was
based on the value of the fluorescence peak channel
number (FL.PK.CH.). At least 104cells were
analyzed in each sample and fluorescence signals
due to autofluorescence represented <2% of the
population.
Cell cycle phase distribution analysis were carried
out in a Becton-Dickinson FACS IV multi-
parameter cell sorter using propidium iodide
stained nuclei of the cells. Briefly, control and
treated cells were washed twice with ice-cold 0.85%
sodium chloride solution and the cell pellet
resuspended in hypotonic propidium iodide staining
solution (Krishan, 1975). The nuclei were
maintained at 4°C for 24h in the staining solution
prior to analysis for cell cycle traverse
perturbations. At least 104 nuclei were analyzed in
each sample, and the fraction of cells in G1, S, and
G2 +M phases of the cell cycle determined as
reported previously (Yen & Fairchild, 1982).
Data on cellular DAU and DOX fluorescence,
cell cycle phase distribution and survival in soft
agar of P388/DOX cells treated with DAU and
DOX in the absence and presence of TFP for 3 h,
6h and 24h are presented in Table I. Additionally,
representative histograms of data in Table I,
showing cellular DAU and DOX fluorescence
profiles and the corresponding DNA distribution
histograms with cell cycle phase distributions,
following treatment of P388/DOX cells with DAU
and DOX in the absence and presence of TFP for
24h are presented in Figure 1. In P388/DOX cells
treated with 5 UM TFP alone for 24h, survival was
100% of control, and although calmodulin
inhibitors affect cell cycle traverse (Chafouleas et
al., 1982) no changes in cell cycle phase distribution
were apparent at the concentration of TFP used in
this study. Cell to cell heterogeneity in DOX uptake
based on FL/LS ratio, was apparent only in
P388/DOX cells treated for 24h with 0.25pgml-'
but not 0.5jgml-1 and 1.O0igml-1 DOX. In
P388/DOX cells treated with DOX alone the
enhancement in fluorescence intensity (based on the
value of FL.PK.CH.) paralleled increases in
doxorubicin concentration, but cell cycle phase
distribution and survival in soft-agar was found to
be independent of the extracellular DOX
concentration and comparable to the untreated
control. Similarly, in P388/DOX cells treated with
DOX alone for 3h and 6h no significant alterations
in cell cycle traverse or cytotoxicity were observed.
In contrast to these results, cellular DOX
fluorescence, cell cycle traverse and survival in soft-
agar were remarkably different in P388/DOX cells
treated with DOX plus 5gM TFP for 24h. No cell
to cell heterogeneity in cellular fluorescence was
observed, and DOX fluorescence was - 2-fold
higher in TFP treated P388/DOX cells. In the
presence of TFP, a reduction of cells in G1 and S
phases of the cell cycle and a corresponding
increase in G2+M phase was evident with increases
in DOX concentration. Furthermore, these
perturbations in cell cycle traverse were
accompanied by reductions in colony formation ofTFP ON CELL CYCLE AND CELL KILL IN DOX-RESISTANCE 563
Table I Effect of the calmodulin inhibitor trifluoperazine on cellular fluorescence, cell cycle phase
distribution and survival in soft-agar of doxorubicin-resistant P388 mouse leukaemia cells treated with
doxorubicin and daunorubicin
% Fluorescent cellsl Cell cyclephase distributiona
fluorescence peak Survivalb
Treatment channela G1 S G2+M (% ofcontrot)
24h treatment
Control 28% 61% 11%
5pM TFP 29% 59% 12% 100%
DOX 0.25pgml-1 70/10 29% 59% 12% 99%
DOX 0.25pgml -'+5M TFP 99/12 25% 42% 33% 15%
DOX 0.5Mgml-1 100/13 29% 59% 12% 96%
DOX 0.5pgml-'+5pM TFP 100/25 16% 26% 58% 0.7%
DOX 1.0pgml-1 100/22 29% 53% 18% 87%
DOX 1.0pgml -1+5M TFP 100/54 0% 18% 82% 0.7%
DAU 0.1ugml-' 50/10 29% 54% 17% 95%
DAU0.1gml -1+5pMTFP 100/14 25% 40% 35% 6%
DAU 0.25 igml-1 100/14 29% 56% 15% 100%
DAU 0.25pgml-'+ 5M TFP 100/36 0% 8% 92% 0.9%
DAU 0.5/igml-1 100/29 27% 53% 20% 80%
DAU 0.5pgml-1+5pM TFP 100/120 0% 5% 95% 0.7%
3h and 6h treatment
DOX 0.5Mgml '-6h 28% 61% 11% 98%
DOX 0.5pgml 1+SuM TFP 3h 32% 52% 16% 70%
DOX0.5pgml +5pMTFP-6h 26% 51% 23% 36%
DOX2.0pgml-1-6h 29% 56% 15% 90%
DOX 2.0ygml-'+S uMTFP-3h 31% 43% 26% 9.5%
DOX 2.0upgml-'+5iM TFP-6h 00% 17% 83% 2.0%
a% Fluorescent cells/fluorescence peak channel and cell cycle phase distribution are from a representative
experiment; the standard deviations in replicate experiments were <15% of the means. bMean value from
triplicate plates in duplicate experiments; the standard deviations were < 15% of the means. Survival is based
on colony counts.
treated P388/DOX cells in soft-agar. At
concentrations of 0.25kgml-1 DOX and 0.5 to
1.OjugmI-P DOX, the survival of P388/DOX cells
treated with TFP was 15% and 0.7% respectively.
Although, significant perturbations in cell cycle
traverse of P388/DOX cells treated for 3 h and 6h,
were apparent only at 2.0 ugml- 1 DOX+5pM
TFP, cell kill in the presence of TFP was greater
with increasing length of drug exposure both at
0.5,gml-1 and 2.0,gmlV-1 DOX.
The results on the effect of DAU or DAU+ 5gM
TFP on cellular fluorescence, cell cycle traverse and
cytotoxicity were similar to those described earlier
with DOX. Additionally, in agreement with our
earlier observations, on a molar basis, DOX was
- 2-fold less potent than DAU in the presence of
TFP (Ganapathi et al., 1984a).
DOX-resistant cells are cross-resistant to DAU as
well as lipophilic semisynthetic derivatives of DOX
and DAU which differ in their cellular
pharmacokinetics and binding properties to DNA
(Ganapathi et al., 1985). The results from the
present study demonstrate, that in P388/DOX cells,
at comparable cellular DAU or DOX levels,
accumulation of cells in G2 phase of the cell cycle
and a reduction in colony formation due to
enhanced cytotoxicity occurs only in the presence
of TFP. In an earlier study using FCM to analyze
the effects of TFP on DOX levels in P388/DOX
cells treated for 2h, it was observed that cell to cell
heterogeneity in DOX fluorescence was apparent
only in the absence of TFP. Based on these results,
an enhanced cytotoxic effect with DOX in the
presence of TFP was suggested to be due to a
reduction in the heterogeneity of DOX
accumulation (Ganapathi et al., 1984b). Data from
this study with P388/DOX cells treated for 24h
without TFP, indicates that cell to cell
heterogeneity in DAU and DOX fluorescence is
apparent only at the lower concentrations of
0.1 Mgml -P1 DAU and 0.25 ugml-P DOX. In
contrast, following treatment with TFP, both an
absence of cell to cell heterogeneity in anthracycline
accumulation and - 2-fold enhancement in DAU
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Figure 1 Representative histograms of data from Table I demonstrating the effect of the calmodulin inhibitor
trifluoperazine on cellular fluorescence and cell cycle traverse of doxorubicin-resistant P388 mouse leukaemia
cells treated with 0.25pgml-1 daunorubicin (a, b, e and f) and0.5lpgml-' doxorubicin (c, d, g and h).
and DOX fluorescence was observed. Based on data
in Figure 1, it can be argued that enhanced
cytotoxicity with DAU and DOX in the presence of
TFP is due to higher cellular anthracycline
accumulation. However, it is apparent from the
results in Table I, that at comparable cellular levels
and cell to cell distribution of DAU and DOX
fluorescence in P388/DOX cells, treated with two-
fold higher concentrations of DAU or DOX in the
absence of TFP versus half the concentration of
DAU or DOX in the presence of TFP (e.g.
0.25pgml-P DAU versus 0.lygml-' DAU+5pM
TFP; 0.5pgml-' DAU versus 0.25ugml-' DAU
+54uM TFP; 0.5pgmlPt DOX versus 0.25upgml-1
DOX+5pM TFP; and 1.OpgmlP- DOX versus
0.5pgml-P DOX+ 5M TFP), cell kill occurs only
with TFP treatment. Thus, cellular levels per se do
not appear to be a primary determinant of
cytotoxicity or resistance to DAU and DOX in
P388/DOX cells. Thin layer chromatographic
analysis of extracts from P388/DOX cells treated
with DAU and DOX, revealed little if any
breakdown of drug, suggesting that resistance is
probably not due to metabolism of drug to an
inactive species (unpublished observations). Studies
with DOX have demonstrated that an accumulation
of cells in the G2 phase of the cell cycle is related
to a cytotoxic effect (Krishan & Frei, 1976). Since
the P388/DOX cells were treated continuously with
DAU and DOX for 24h, which is - 2 cell cycle
times, it appears that in the absence of TFP, the
ability of the cells to overcome the G2 block may
be a determinant of resistance. Induction of cell
cycle traverse perturbations in P388/DOX cells
treated with DAU and DOX in the presence of
TFP, is unrelated to the antiproliferative effects of
the calmodulin inhibitor, since no cytotoxicity or
alterations in cell cycle phase distribution were
observed with TFP alone. It is therefore possible,
that in the presence of TFP, the P388/DOX cellsTFP ON CELL CYCLE AND CELL KILL IN DOX-RESISTANCE 565
are unable to overcome the damage induced by
DAU and DOX, which result in cell cycle traverse
perturbations and cytotoxicity. This is supported by
some of our recent studies, where we have found
that a reversal of DOX induced G2 block which
parallels reduced cytotoxicity, does not occur in the
presence of 5pM TFP (unpublished observations).
Resistance to DOX appears to be multifactorial
(Ganapathi et al., 1984a; Kessel & Wilberding,
1985) since treatment with TFP does not restore
DOX-sensitivity comparable to the parent-sensitive
line. The results from this study demonstrating a
lack of relationship between cellular DOX and
DAU levels and cytotoxicity are also supported by
the recent study of Chang and Gregory (1985),
wherein inherent resistance to DOX in pancreatic
adenocarcinoma was found to be unrelated to
cellular DOX levels. In summary, this study
suggests, that the expression of resistance to the
cytotoxic effects of DAU and DOX in DOX-
resistant P388 mouse leukaemia cells is unrelated to
gross cellular drug levels, and that treatment with
TFP (which may alter intracellular compart-
mentalization of DAU and DOX) results in the
induction and expression of damage caused by
DAU and DOX. Although membrane alterations
have been implicated to mediate DOX-resistance by
altering drug permeation (Kartner et al., 1983), it
appears that a delineation of the intracellular
mechanism of action of DAU and DOX may greatly
aid our understanding of the phenomenon of
resistance to these clinically important DNA-
binding anthracyclines.
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